BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37650266)

  • 1. Raman spectroscopy and U-Net deep neural network in antiresorptive drug-related osteonecrosis of the jaw.
    Matthies L; Gebrekidan MT; Braeuer AS; Friedrich RE; Stelzle F; Schmidt C; Smeets R; Assaf AT; Gosau M; Rolvien T; Knipfer C
    Oral Dis; 2024 May; 30(4):2439-2452. PubMed ID: 37650266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.
    Matthies L; Amir-Kabirian H; Gebrekidan MT; Braeuer AS; Speth US; Smeets R; Hagel C; Gosau M; Knipfer C; Friedrich RE
    PLoS One; 2024; 19(4):e0302017. PubMed ID: 38603731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Periodontal Space Widening in Patients with Antiresorptive Drug-related Osteonecrosis of the Jaws (ARONJ) on Panoramic Radiographs.
    Assaf AT; Amberg V; Smeets R; Wikner J; Hanken H; Semmusch J; Ewald F; Rashad A; Friedrich RE
    Anticancer Res; 2018 Sep; 38(9):5305-5314. PubMed ID: 30194182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular alterations of bone quality in sequesters of bisphosphonates-related osteonecrosis of the jaws.
    Olejnik C; Falgayrac G; During A; Vieillard MH; Maes JM; Cortet B; Penel G
    Osteoporos Int; 2014 Feb; 25(2):747-56. PubMed ID: 24081510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
    Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships of opacification in the nasal sinuses, rhinosinusitis, and antiresorptive agent-related osteonecrosis of the jaw.
    Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Saito K
    Auris Nasus Larynx; 2020 Dec; 47(6):996-1002. PubMed ID: 32591168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
    Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
    J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.
    Fujieda Y; Doi M; Asaka T; Ota M; Hisada R; Ohnishi N; Kono M; Kameda H; Nakazawa D; Kato M; Amengual O; Takahata M; Yasuda S; Kitagawa Y; Atsumi T
    J Bone Miner Metab; 2020 Jul; 38(4):581-588. PubMed ID: 32076874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
    Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
    J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.
    Kanno C; Kaneko T; Endo M; Kitabatake T; Sakuma T; Kanaya Y; Watanabe Y; Hasegawa H
    J Bone Miner Metab; 2021 May; 39(3):423-429. PubMed ID: 33196901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
    Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
    PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.
    ; Yoneda T; Hagino H; Sugimoto T; Ohta H; Takahashi S; Soen S; Taguchi A; Nagata T; Urade M; Shibahara T; Toyosawa S
    J Bone Miner Metab; 2017 Jan; 35(1):6-19. PubMed ID: 28035494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience.
    Bernardi S; Di Girolamo M; Necozione S; Continenza MA; Cutilli T
    Musculoskelet Surg; 2019 Apr; 103(1):47-53. PubMed ID: 29948937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis.
    Fujieda Y; Atsumi T
    J Bone Miner Metab; 2020 Sep; 38(5):739-741. PubMed ID: 32591907
    [No Abstract]   [Full Text] [Related]  

  • 17. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.
    Nashi M; Hirai T; Iwamoto T; Takenobu T
    J Bone Miner Metab; 2022 Nov; 40(6):1014-1020. PubMed ID: 36166107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
    Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incidence of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Urologic Cancers].
    Kawanishi H; Yokozeki H; Hoshiyama A; Watanabe H; Funahashi Y; Fujiwara M; Takashima Y; Shintani M; Yui S; Okumura K
    Hinyokika Kiyo; 2022 Jan; 68(1):1-6. PubMed ID: 35114759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.